BA (hons), BMBCh (hons), MRCP, DPhil (Oxon)
Associate Professor of Cardiovascular Medicine
- British Heart Foundation Intermediate Clinical Research Fellow
- Deputy Clinical Director of OCMR
- Honorary Consultant Cardiologist
After studying medicine at Pembroke College (1996-2002) I completed the Royal College Examinations and specialized in Cardiology. In 2005 I was awarded a Wellcome Trust Junior Research Fellowship to complete my DPhil in Cardiovascular medicine at Oxford, where I used advanced cardiac magnetic resonance imaging and spectroscopy to study the effects of obesity and weight loss on myocardial metabolism and function. For this work I was awarded the American Heart Association Young Investigator Award for Nutrition Physical Activity and Metabolism (2008) and took up the role of Clinical Lecturer in Cardiovascular Medicine in Oxford in 2010 where I furthered my research into obesity. In 2015 I was appointed as an Honorary Consultant Cardiologist and Deputy Clinical Director or the University of Oxford Centre for Clinical Magnetic Resonance Research. I currently hold a British Heart Foundation Intermediate Clinical Research Fellowship and run a research group that uses advanced cardiac magnetic resonance imaging and spectroscopy to investigate the relationship between cardiac substrate metabolism, cardiac energetics and cardiac function in multiple diseases with a focus on obesity, bariatric surgery, heart failure and cardiac hypertrophy.
Investigating the disease is the key to the obesity stigma
RAYNER J. and RIDER O., (2021), European Heart Journal
PARTICIPANTS WITH DIABETES MELLITUS HAVE PRESERVED METABOLIC FLEXIBILITY
Green P. et al, (2021), HEART, 107, A17 - A17
Energetic basis for exercise-induced pulmonary congestion in heart failure with preserved ejection fraction
BURRAGE M. et al, (2021), Circulation
Proof-of-Principle Demonstration of Direct Metabolic Imaging Following Myocardial Infarction Using Hyperpolarized 13C CMR.
Apps A. et al, (2021), JACC Cardiovasc Imaging, 14, 1285 - 1288
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
Hundertmark MJ. et al, (2021), ESC Heart Fail